Calidi Biotherapeutics (NYSE:CLDI) Posts Earnings Results, Beats Expectations By $0.20 EPS

Calidi Biotherapeutics (NYSE:CLDI) released its quarterly earnings results on Tuesday. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.20, Zacks reports.

Calidi Biotherapeutics Trading Up 45.0 %

Shares of CLDI stock traded up $0.95 during mid-day trading on Wednesday, reaching $3.06. 16,929,137 shares of the company were exchanged, compared to its average volume of 347,983. The company has a 50 day moving average price of $1.19. Calidi Biotherapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $26.30.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.